Anticoagulation with bivalirudin during cardiopulmonary bypass in cardiac surgery

Ann Thorac Surg. 2002 Dec;74(6):2177-9. doi: 10.1016/s0003-4975(02)04125-5.

Abstract

Heparin is the standard agent used for systemic anticoagulation during cardiopulmonary bypass in cardiac operations. Alternatives are needed when patients with heparin-induced thrombocytopenia type II are encountered. We present a patient with a clinical picture of heparin-induced thrombocytopenia type II who was effectively anticoagulated with bivalirudin, a direct thrombin inhibitor, during cardiopulmonary bypass for a cardiac operation.

Publication types

  • Case Reports

MeSH terms

  • Anticoagulants / therapeutic use*
  • Cardiac Surgical Procedures*
  • Cardiopulmonary Bypass / methods*
  • Heparin / adverse effects
  • Hirudins / analogs & derivatives*
  • Humans
  • Male
  • Middle Aged
  • Peptide Fragments / therapeutic use*
  • Recombinant Proteins / therapeutic use*
  • Thrombocytopenia / chemically induced

Substances

  • Anticoagulants
  • Hirudins
  • Peptide Fragments
  • Recombinant Proteins
  • Heparin
  • bivalirudin